Difference between revisions of "Gene Therapy versus Human Genome Editing (Biotechnology and Society 2016)"
From SynBioCyc
(→Required Reading/Viewing) |
|||
Line 8: | Line 8: | ||
− | == Everyone: | + | == Everyone: Overview of gene therapy, germline modification, and genome synthesis == |
== Required Reading/Viewing == | == Required Reading/Viewing == | ||
Line 20: | Line 20: | ||
* [http://link.springer.com/chapter/10.1007/978-88-470-1643-9_5 Read Chapter 5: Ethical and Social Problems of Gene Therapy]<br>Access from on-campus to read. | * [http://link.springer.com/chapter/10.1007/978-88-470-1643-9_5 Read Chapter 5: Ethical and Social Problems of Gene Therapy]<br>Access from on-campus to read. | ||
− | == | + | == CRISPR Germline Modification Czar == |
− | + | * [http://gizmodo.com/everything-you-need-to-know-about-crispr-the-new-tool-1702114381 Everything You Need to Know About CRISPR, the New Tool that Edits DNA] Sarah Zhang ''Gizmodo'' May 6, 2015. | |
− | + | * Lanphier, E., Urnov, F., Haecker, S.E., Werner, M., and Smolenski, J. (2015). [http://www.nature.com/news/don-t-edit-the-human-germ-line-1.17111 Don’t edit the human germ line.] ''Nature'' '''519''': 410–411. | |
− | + | ||
− | * | + | |
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | + | ||
− | == | + | == Gene Therapy Czar == |
==== Required Reading/Viewing ==== | ==== Required Reading/Viewing ==== | ||
− | * Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. ''J. Clin. Invest.'' '''118''':3132–3142. <br> | + | * Bryant, L.M., Christopher, D.M., Giles, A.R., Hinderer, C., Rodriguez, J.L., Smith, J.B., Traxler, E.A., Tycko, J., Wojno, A.P., and Wilson, J.M. (2013). [https://www.ncbi.nlm.nih.gov/pubmed/23808604 Lessons learned from the clinical development and market authorization of Glybera.] ''Hum. Gene Ther. Clin. Dev.'' '''24''':55–64. <br>Chronicles the development of the first commercially available gene therapy treatment for Familial Lipoprotein Lipase Deficiency (LPLD). |
+ | * Glybera [http://www.uniqure.com/products/glybera/ Glybera] - commercial gene therapy product. | ||
+ | * Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. ''J. Clin. Invest.'' '''118''':3132–3142. <br>Scan for the major take-home message. |
Revision as of 13:38, 30 October 2016
Download Pre-Discussion Questions (MS Word)
Download Policy Czar Template (MS Word)
Everyone: Overview of gene therapy, germline modification, and genome synthesis
Required Reading/Viewing
- Gene Therapy emerges from disgrace to be the next big thing, again. Carl Zimmer Wired Science Blogs August 13, 2013.
- Engineering the Perfect Baby Antonio Regalado MIT Technology Review March 5, 2015.
Use of CRISPR to - Scientists reveal proposal to build human genome from scratch Kelly Servick Science June 2, 2016.
Short article describing the Human Genome Project–Write meeting.
Additional Resources
- Gene Therapy: Molecular Bandage? Educational website at the University of Utah.
Especially, check out the "Tools of the Trade" and "Space Doctor" links. - Read Chapter 5: Ethical and Social Problems of Gene Therapy
Access from on-campus to read.
CRISPR Germline Modification Czar
- Everything You Need to Know About CRISPR, the New Tool that Edits DNA Sarah Zhang Gizmodo May 6, 2015.
- Lanphier, E., Urnov, F., Haecker, S.E., Werner, M., and Smolenski, J. (2015). Don’t edit the human germ line. Nature 519: 410–411.
Gene Therapy Czar
Required Reading/Viewing
- Bryant, L.M., Christopher, D.M., Giles, A.R., Hinderer, C., Rodriguez, J.L., Smith, J.B., Traxler, E.A., Tycko, J., Wojno, A.P., and Wilson, J.M. (2013). Lessons learned from the clinical development and market authorization of Glybera. Hum. Gene Ther. Clin. Dev. 24:55–64.
Chronicles the development of the first commercially available gene therapy treatment for Familial Lipoprotein Lipase Deficiency (LPLD). - Glybera Glybera - commercial gene therapy product.
- Hacein-Bey-Abina, S., Garrigue, A., Wang, G.P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008). Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J. Clin. Invest. 118:3132–3142.
Scan for the major take-home message.